Scientific Reports (Aug 2024)

Deep learning predicts the 1-year prognosis of pancreatic cancer patients using positive peritoneal washing cytology

  • Aya Noguchi,
  • Yasushi Numata,
  • Takanori Sugawara,
  • Hiroshu Miura,
  • Kaori Konno,
  • Yuzu Adachi,
  • Ruri Yamaguchi,
  • Masaharu Ishida,
  • Takashi Kokumai,
  • Daisuke Douchi,
  • Takayuki Miura,
  • Kyohei Ariake,
  • Shun Nakayama,
  • Shimpei Maeda,
  • Hideo Ohtsuka,
  • Masamichi Mizuma,
  • Kei Nakagawa,
  • Hiromu Morikawa,
  • Jun Akatsuka,
  • Ichiro Maeda,
  • Michiaki Unno,
  • Yoichiro Yamamoto,
  • Toru Furukawa

DOI
https://doi.org/10.1038/s41598-024-67757-5
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Peritoneal washing cytology (CY) in patients with pancreatic cancer is mainly used for staging; however, it may also be used to evaluate the intraperitoneal status to predict a more accurate prognosis. Here, we investigated the potential of deep learning of CY specimen images for predicting the 1-year prognosis of pancreatic cancer in CY-positive patients. CY specimens from 88 patients with prognostic information were retrospectively analyzed. CY specimens scanned by the whole slide imaging device were segmented and subjected to deep learning with a Vision Transformer (ViT) and a Convolutional Neural Network (CNN). The results indicated that ViT and CNN predicted the 1-year prognosis from scanned images with accuracies of 0.8056 and 0.8009 in the area under the curve of the receiver operating characteristic curves, respectively. Patients predicted to survive 1 year or more by ViT showed significantly longer survivals by Kaplan–Meier analyses. The cell nuclei found to have a negative prognostic impact by ViT appeared to be neutrophils. Our results indicate that AI-mediated analysis of CY specimens can successfully predict the 1-year prognosis of patients with pancreatic cancer positive for CY. Intraperitoneal neutrophils may be a novel prognostic marker and therapeutic target for CY-positive patients with pancreatic cancer.